Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Shares Sold by BVF Inc. IL

BVF Inc. IL reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 37.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,715,893 shares of the company's stock after selling 3,420,000 shares during the period. Olema Pharmaceuticals accounts for about 1.1% of BVF Inc. IL's holdings, making the stock its 22nd biggest position. BVF Inc. IL owned about 9.98% of Olema Pharmaceuticals worth $33,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Balyasny Asset Management L.P. raised its holdings in shares of Olema Pharmaceuticals by 59.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,127,589 shares of the company's stock worth $6,574,000 after acquiring an additional 418,492 shares during the last quarter. Bank of America Corp DE lifted its holdings in Olema Pharmaceuticals by 110.6% in the 4th quarter. Bank of America Corp DE now owns 865,339 shares of the company's stock valued at $5,045,000 after purchasing an additional 454,400 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Olema Pharmaceuticals during the 4th quarter worth about $1,130,000. Boxer Capital Management LLC purchased a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth about $3,790,000. Finally, Schonfeld Strategic Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 9.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 505,400 shares of the company's stock worth $2,946,000 after buying an additional 43,474 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Price Performance

OLMA stock traded down $0.96 on Tuesday, hitting $4.60. 1,631,984 shares of the company were exchanged, compared to its average volume of 872,519. The stock has a market capitalization of $314.46 million, a price-to-earnings ratio of -2.10 and a beta of 2.03. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $16.62. The business's fifty day moving average is $4.25 and its two-hundred day moving average is $6.48.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.12. Equities research analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on OLMA. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Olema Pharmaceuticals in a research report on Monday, April 28th. JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating on the stock in a report on Friday, March 28th. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $25.00 price objective (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.